Compare ETB & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Current Price
| Metric | ETB | ENTA |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.8M | 486.3M |
| IPO Year | N/A | 2013 |
| Metric | ETB | ENTA |
|---|---|---|
| Price | $15.41 | $12.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 71.8K | ★ 244.7K |
| Earning Date | 01-01-0001 | 02-09-2026 |
| Dividend Yield | ★ 8.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $65,324,000.00 |
| Revenue This Year | N/A | $0.99 |
| Revenue Next Year | N/A | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.59 | $4.09 |
| 52 Week High | $14.08 | $17.15 |
| Indicator | ETB | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 42.98 |
| Support Level | $15.31 | $12.32 |
| Resistance Level | $15.58 | $13.03 |
| Average True Range (ATR) | 0.16 | 0.63 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 77.39 | 39.68 |
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.